Shimanovich I, Baumann T, Schmidt E, et al. - Since rituximab induces a rapid remission in most patients with pemphigus, researchers performed this retrospective study to determine the long‐term effectiveness of rituximab in this disease. The sample consisted of 59 patients with pemphigus treated with rituximab and observed over a median period of 104 months. After the first rituximab cycle, the rate of complete remission off therapy (CRoff) was 39%, increasing to 61% with additional rituximab courses. In 27% of patients, long‐term CRoff has been achieved. After the first rituximab cycle, the rate of recurrence was 63%, declining to nearly 40% with subsequent rituximab cycles. No significant difference was found in age, gender, pemphigus subtype, rituximab dosing and disease duration between patients achieving CRoff and those not meeting this endpoint. Lower baseline antibody levels specific to desmoglein were predictive of CRoff. Complete remission after the first cycle was linked to a favourable long‐term outcome in patients receiving multiple rituximab cycles. Repeated courses of rituximab were highly successful for relapsed disease and improved the overall result.